Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 8, 2009, Pages 2220-2223

  Benbow, John W ^a   Andrews, Kim A ^a   Aubrecht, Jiri ^a   Beebe, David ^a   Boyer, David ^a   Doran, Shawn ^a   Homiski, Michael ^a   Hui, Yu ^a   McPherson, Kirk ^a   Parker, Janice C ^a   Treadway, Judith ^a   VanVolkenberg, Maria ^a   Zembrowski, William J ^a  

^a PFIZER INC   (United States)

Author keywords

Dipeptidyl peptidase IV; DPP IV; Phenethylamine

Indexed keywords

1 AMINO 2 (2,4,5 TRIFLUORO)PHENYLETHANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PHENETHYLAMINE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN; CHO CELL; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MICRONUCLEUS TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATCH CLAMP; PHARMACODYNAMICS; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; HUMANS; HYPOGLYCEMIC AGENTS; PHENETHYLAMINES; PIPERIDINES; RATS;

RATTUS;

EID: 63149164408     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.099     Document Type: Article

References (14)

1. Flier J.S. Cell 116 (2004) 337
2. Hogan P., et al. Diabetes Care 26 (2003) 917
3. Pei Z. Curr. Opin. Drug Disc. Dev. 11 (2008) 512
4. Flatt P.R., et al. Front. Biosci. 13 (2008) 3648
5. Drucker D.J. Endocrinology 144 (2003) 5145
6. Bioluminescent Salmonella assay:. Aubrecht J., et al. Mutagenesis 22 (2007) 335
7. The in vitro micronucleus assay:. Sobol Z., et al. Mutation Res. 633 (2007) 80
8. Over the course of the DPP-IV project, over 30 crystal structure solutions were prepared, some of which have been published:. Wright S.W., et al. Bioorg. Med. Chem. Lett. 17 (2007) 5638
9. Corbett J.W., et al. Bioorg. Med. Chem. Lett. 17 (2007) 6707
10. Irako N., et al. Tetrahedron 51 (1995) 12731
11. The in vitro micronucleus assay detects the presence of extra-nuclear chromatin (micronuclei) in cytoplasm as a consequence of either chromosome loss (aneugenicity) or chromosome breakage (clastogenicity). These effects can be differentiated via evaluating the kinetochore complex in micronuclei:. Schuler M., et al. Mutation Res. 392 (1997) 81
12. The higher throughput in vitro micronucleus assay utilizes standard microplate technology, automated imaging using the Cellomics ArrayScan VTI (Thermo Fisher Scientific, Rockford, IL) and an image analysis scoring algorithm developed from an Image-Pro software platform (MediaCybernetics, Bethesda, MD). The results generated on set of test compounds using this assay compared favorably with those generated via the standard microscopic analysis.
13. 50 value, and 'I' is the unbound plasma concentration.
14. A low dose (<50 mg q.d.) was desired to lower the risk of idiosyncratic toxicity in the clinic:. Kalgutkar A.S., et al. Exp. Rev. Clin. Pharmacol. 1 (2008) 515